Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA258
Published: 27 June 2012

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix A - GE decision paper - December 2014

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix A - GE decision paper - December 2014

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix A - GE decision paper - December 2014
15 December 2014
(495.7 Kb 24 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 12 December 2014